diciembre 12, 2019 +34 91 3612600 sei2017@kenes.com
Languages
  • Español
SEI 2017. 40 Congreso de la Sociedad Española de Inmunologia. Zaragoza 25-27 mayo SEI 2017. 40 Congreso de la Sociedad Española de Inmunologia. Zaragoza 25-27 mayo SEI 2017. 40 Congreso de la Sociedad Española de Inmunologia. Zaragoza 25-27 mayo SEI 2017. 40 Congreso de la Sociedad Española de Inmunologia. Zaragoza 25-27 mayo
  • Inicio
  • INFORMACIÓN GENERAL
    • PRESENTACIÓN
    • COMITÉS
    • ORGANIZADO POR
    • SEDE
    • INFORMACIÓN GENERAL
    • CONTACTO
  • INFORMACIÓN CIENTÍFICA
    • PROGRAMA CIENTÍFICO
    • ESQUEMA DE HORARIOS
    • PONENTES DE LAS PLENARIAS
    • MINISIMPOSIO «INMUNOTERAPIA DEL CÁNCER»
    • APP DEL CONGRESO
  • COMUNICACIONES
    • ENVÍO DE COMUNICACIONES Y CASOS CLÍNICOS
    • BECAS
    • GUIA PARA PRESENTAR LAS COMUNICACIONES DURANTE EL CONGRESO
  • INSCRIPCIÓN
  • ALOJAMIENTO
  • PATROCINIOS Y EXPOSICIÓN
    • PATROCINIOS Y EXPOSICIÓN
    • PATROCINADORES CONFIRMADOS
  • ZARAGOZA
  • Inicio
  • INFORMACIÓN GENERAL
    • PRESENTACIÓN
    • COMITÉS
    • ORGANIZADO POR
    • SEDE
    • INFORMACIÓN GENERAL
    • CONTACTO
  • INFORMACIÓN CIENTÍFICA
    • PROGRAMA CIENTÍFICO
    • ESQUEMA DE HORARIOS
    • PONENTES DE LAS PLENARIAS
    • MINISIMPOSIO «INMUNOTERAPIA DEL CÁNCER»
    • APP DEL CONGRESO
  • COMUNICACIONES
    • ENVÍO DE COMUNICACIONES Y CASOS CLÍNICOS
    • BECAS
    • GUIA PARA PRESENTAR LAS COMUNICACIONES DURANTE EL CONGRESO
  • INSCRIPCIÓN
  • ALOJAMIENTO
  • PATROCINIOS Y EXPOSICIÓN
    • PATROCINIOS Y EXPOSICIÓN
    • PATROCINADORES CONFIRMADOS
  • ZARAGOZA

Organizado por

Sociedad Española de Inmunología (SEI)

www.inmunologia.org

  • PRESENTACIÓN
  • COMITÉS
  • ORGANIZADO POR
  • SEDE
  • INFORMACIÓN GENERAL
  • CONTACTO
  Manténgase Informado
  Pulsa aquímobile-sei2017
ORGANIZADO POR
logos-footer
MENÚ RÁPIDO
  • INSCRIPCIÓN
  • ENVÍO DE COMUNICACIONES Y CASOS CLÍNICOS
  • PATROCINIOS Y EXPOSICIÓN
CONTACTO
  • KENES GROUP
  • +34 91 361 2600
  • sei2017@kenes.com
  • congreso-inmunologia.com
Síguenos en
kenes-group
Contacto

Envíenos un mensaje y le contestaremos lo antes posible.

Not readable? Change text. captcha txt
Dr. Federica Sallusto

Short CV

Federica SallustoDr. Federica Sallusto

Cellular Immunology Laboratory and Center of Medical Immunology, Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland
Federica Sallusto received the degree of Doctor in Biology from the University of Rome in 1988, and performed postdoctoral work at the Istituto Superiore di Sanità in Rome and at the Basel Institute for Immunology, where she was a member from 11/1996 to 4/2000. She is currently Group leader of the Cellular Immunology Laboratory and Director of the Center of Medical Immunology at the Institute for Research in Biomedicine, Università della Svizzera italiana, in Bellinzona, and since February Professor of Medical Immunology at the ETH Zurich. Her studies in the human system revealed a differential expression of chemokine receptors in Th1 and Th2 cells and led to the characterization of “central memory” and “effector memory” T cells as memory subsets with distinct migratory capacity and effector function. Among her recent contributions are the discovery of Th22 cells, the identification of markers to identify human Th17 cells and the characterization of two distinct types of pathogen-specific Th17 cells that produce IFN- or IL-10. She received the Pharmacia Allergy Research Foundation Award in 1999, the Behring Lecture Prize in 2009 and was elected member of the German Academy of Science Leopoldina in 2009 and of EMBO in 2011. In 2013-2015 she was President of the Swiss Society for Allergology and Immunology.

http://www.irb.usi.ch/cellular-immunology

Prof. Guido Kroemer

Short CV

Prof. Guido Kroemer

Guido Kroemer is currently Professor at the Faculty of Medicine of the University of Paris Descartes, Director of the research team «Apoptosis, Cancer and Immunity» of the French Medical Research Council (INSERM), Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Comprehensive Cancer Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France. He is also a Foreign Adjunct Professor at the Karolinska Institute, Stockholm, Sweden.
Prior to joining INSERM (1994), Dr. Kroemer was Senior Scientist of the European Community at the Spanish National Research Council (CSIC), at the National Center of Molecular Biology (1990-1992) and at the National Center of Biotechnology (1993). Dr. Kroemer did his post-doctoral training at the Collège de France, Nogent-sur-Marne (1988-1989) and at the University of Innsbruck, Austria, after receiving his PhD/MD degree at the same University in 1985. He also holds a PhD degree in Molecular Biology (Autonomous University of Madrid, 1992).
Dr. Guido Kroemer has made important contributions to medical research through his groundbreaking work in the fields of cell biology and cancer research. He is best known for the discovery that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death. Kroemer has explored the fine mechanisms of mitochondrial cell death control, the molecular pathways that explain the inhibition of cell death in cancer cells, upstream of or at the level of mitochondria, and the mechanisms that make cancer cell death immunogenic. His work has had far reaching implications for the comprehension, detection and therapeutic manipulation of cellular demise. He has published some 1000 papers including in Science (12x), Cell (10x), Nature (5x), Nature Medicine (12x), Journal of Experimental Medicine (25x), EMBO Journal (17x), Journal of Clinical Investigation (15x), Molecular Cell (12x), Nature Cell Biology (11x), Cell Research (8x), Immunity (7x), Cell Metabolism (5x), Journal of Cell Biology (5x), Cancer Cell (4x), Science Translational Medicine (3x), Nature Structural Biology (2x), Proceedings of the National Academy of Sciences of the USA (2x), Nature Communications, and New England Journal of Medicine.
Guido Kroemer’s contributions have been recognized with numerous awards, including the Monika Kutzner Prize of the Berlin-Brandenburg Academy of Sciences (1998), the Gallet & Breton Prize of the French Academy of Medicine (1999), the Descartes Prize of the European Union (2006), the Carus Medal of the German Academy of Sciences (2007), the Grand Prix Mergier-Bourdeix of the French Academy of Sciences (2007), the Lucien Dautrebande Prize of the Belgian Royal Academy of Medicine (2009), the Duquesne Prize of the French National League against Cancer (2010), the «Coup d’Elan» Prize of the Bettencourt-Schueller Foundation (2011), the Léopold Griffuel Prize of the French Association for Cancer Research (2012), an Advanced Investigator Award from the European Research Council (2013), the Mitjavile Prize of the French Academy of Medicine (2014), the Galien Prize for Pharmacological Resarch (2015), the Grand Prix Claude Bernard of the City of Paris (2016), and the Brupbacher Prize for Cancer Research (2017), among others.
Guido Kroemer currently serves on the Editorial Boards of Cell Death & Differentiation, Cell Research, EMBO Journal, EMBO Molecular Medicine, Oncogene, Oncotarget, Molecular & Cellular Biology, and Science Signaling. Kroemer is also the founding Editor-in-Chief of four journals, Cell Death & Disease, OncoImmunology, Microbial Cell, and Molecular & Cellular Oncology. He is member of the European Molecular Biology Organization (EMBO), German Academy of Sciences (Leopoldina), Austrian Academy of Sciences, Academia Europaea, European Academy of Sciences (EAS), European Academy of Sciences and Arts (EASA), European Academy of Cancer Sciences (EACS), and Institut Universitaire de France (IUF). He is the Director of the Paris Alliance of Cancer Research Institutes (PACRI), the Founding Director of the European Research Institute for Integrated Cellular Pathology (ERI-ICP), and the Founding President of the European Academy of Tumor Immunology (EATI).
Dr. Marina A. Dobrovolskaia

Short CV

marina-a-dobrovolskaiaDr. Marina A. Dobrovolskaia

Dr. Dobrovolskaia is a Senior Principal Scientist, Head of Immunology Section at the Nanotechnology Characterization Laboratory  (NCL) operated by Leidos Biomedical Research Inc. for the US National Cancer Institute. Dr. Dobrovolskaia directs characterization related to nanomaterials’ interactions with components of the immune system. She leads a team of scientists and technicians conducting preclinical studies to monitor acute/adverse effects of nanoparticles to the immune system both in vitro and in vivo using variety of immune function animal models. Dr. Dobrovolskaia’s team develops, validates and qualifies performance of in vitro and ex vivo assays to support preclinical characterization of nanoparticles, and to monitor nanoparticle purity from biological contaminants such as bacteria, yeast, mold and endotoxin. Her group contributed to characterization and evaluation of more than 300 nanotechnology products submitted to the NCL for preclinical characterization; ten of these products are now in human clinical trials. Dr. Dobrovolskaia is a member of several working groups on Nanomedicine, Oligonucleotide Safety and Endotoxin Detection. She has published more than 45 peer-reviewed papers regarding nanomaterial interactions with the immune system, prepared and edited two editions of the “Handbook of Immunological Properties of Engineered Nanomaterials”, which received international recognition. Dr. Dobrovolskaia is an invited speaker to numerous national and international nanotechnology-related conferences. She has served a 4-yar term as a Special Associate Editor in Immunology for the “Nanomedicine: Nanotechnology, Biology and Medicine” Journal published by Elsevier and is currently an editorial board member for the Journal of Nanotoxicology and Nanomedicine by IGI Global.
Prior to joining the NCL, Dr. Dobrovolskaia worked as a Research Scientist in a GLP laboratory at PPD Development, Inc. in Richmond, VA, where she was responsible for the design, development and validation of bioanalytical ligand-binding assays to support pharmacokinetic and toxicity studies in a variety of drug development projects. She received her M.S. degree from the Kazan State University in Russia, her Ph.D. from the N.N. Blokhin Cancer Research Center of the Russian Academy of Medical Sciences in Moscow, Russia, the MBA degree from Hood College In Frederick MD, and completed two postdoctoral trainings at the National Cancer Institute in Frederick, MD and the University of Maryland in Baltimore, MD. She is also a member of Project Management Institute and a certified Project Management Professional. Her areas of expertise include cell signaling, innate immunity, immunotoxicity of complex drug formulations, bioanalytical methodology, and endotoxin detection and quantification.